MedPath

Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-Up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins

Phase 4
Completed
Conditions
Healthy Skin
Interventions
Drug: adapalen 0.1%
Other: Cetaphil®
Registration Number
NCT00971282
Lead Sponsor
Galderma R&D
Brief Summary

This is a single-center study, randomized, Investigator/Evaluator-blinded bilateral (split-face) comparison.

The objective: To assess the benefit of the concomitant use of a Moisturizing Lotion in reducing the skin irritation induced by a adapalen gel treatment in Chinese Subjects.

Detailed Description

The interest \& relevance of the concomitant use of a non-comedogenic moisturizer in order to decrease retinoid irritation has already been demonstrated in Caucasian patients. Such interest of associating a moisturizer when Differin® gel is prescribed has not been demonstrated in Asian populations.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • male or female subjects of Chinese origins
  • aged 21 years or older
  • with healthy skin;
Exclusion Criteria
  • skin pigmentation which interferes with the reading of skin reactions
  • with sunburn, eczema, atopic dermatitis, perioral dermatitis, or rosacea on the area to be treated
  • with a washout period for the following topical treatment(s) Corticosteroids, oher anti-inflammatory drugs, retinoids
  • with a washout period for the following systemic treatment(s): Medications that may increase photosensitivity, corticosteroids, anti-inflammatories, retinoids

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
intra-individual comparisonadapalen 0.1%-
intra-individual comparisonCetaphil®-
Primary Outcome Measures
NameTimeMethod
Pruritusat 4 weeks

score from 0 (none) to 3 (severe)

Scalingat 4 weeks

score from 0 (none) to 3 (severe)

Drynessat 4 weeks

score from 0 (none) to 3 (severe)

Stinging/Burningat 4 weeks

score from 0 (none) to 3 (severe)

Erythema Rating Scaleat 4 weeks

score from 0 (none) to 3 (severe)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

national Skin Center

🇸🇬

Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath